CTRI/2022/09/046021
Not yet recruiting
未知
To evaluate the role of 18F FDG PET-CT for detection of nociceptive metabolic activity in patients with low backache.
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ot applicable
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Participants between the age of 18 and 75\.
- •2\) The ability to give written informed consent.
- •3\) Ongoing pain that averaged at least 4, on a 0\-10 pain scale( visual analogue scale); during a typical week, and present at least 50 percent of days during a typical week.
- •4\) On a stable pain treatment.
- •5\) Medical records confirming the diagnosis of low back pain.
Exclusion Criteria
- •1\) Breastfeeding or pregnancy.
- •2\) blood glucose level \> 150mg/dl.
- •3\) Inability to provide consent.
- •4\) Any suspected spine infection.
- •5\) Any known osseous metastatic or other osseous malignancy.
- •6\) History of major spine trauma or spinal surgery within six months from the time of scanning.
- •7\) Any interventional pain procedures within six weeks before scanning procedure or at any point during study enrollment.
- •8\) Past or current history of major psychiatric ilness e.g anxiety, claustrophobia, etc.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The Value of PET-CT in Pleural EffusionsPleural Effusion, MalignantNCT03272997Naestved Hospital112
Unknown
Early Phase 1
18F-FDG PET/CT for IgG4-Related DiseaseAutoimmune DiseaseNCT01665196Peking Union Medical College Hospital100
Completed
Not Applicable
PLACE OF THE 18F-FDG-PET/CT IN THE DIAGNOSTIC WORKUP IN PATIENTS WITH CLASSICAL FEVER OF UNKNOWN ORIGIN (FUO)Fever of Unknown OriginNCT04851379University Hospital, Montpellier44
Completed
Not Applicable
Evaluation of 18F-FDG-PET/CT in the diagnosis and treatment response of bone metastasis.bone metastasisJPRN-UMIN000005866ational Cancer Center Research Projects Management expenses Grants from the Government to National Cancer Research Center220
Active, not recruiting
Phase 1
Study to see if new research scans can show how treatment affects the blood supply to kidney cancersPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-002833-20-GBOxford University Hospitals NHS Trust10